A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03422445

Recruitment Status : Unknown

Verified January 2018 by Jun Guo, Peking University Cancer Hospital & Institute.
Recruitment status was: Recruiting

First Posted : February 5, 2018

Last Update Posted : February 5, 2018

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Jun Guo, Peking University Cancer Hospital & Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	February 2019
Estimated Study Completion Date :	February 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhou L, Yang Y, Si L, Chi Z, Sheng X, Lian B, Wang X, Tang B, Mao L, Yan X, Li S, Bai X, Guo J, Cui C. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma Res. 2022 Jun 1;32(3):142-149. doi: 10.1097/CMR.0000000000000809. Epub 2022 Feb 20.

To Top